Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected
Sign Up to like & getrecommendations! Published in 2020 at "EMBO Molecular Medicine"
DOI: 10.15252/emmm.202012921
Abstract: In Alzheimer’s disease (AD), tau phosphorylation in the brain and its subsequent release into cerebrospinal fluid (CSF) and blood is a dynamic process that changes during disease evolution. The main aim of our study was… read more here.
Keywords: alzheimer continuum; preclinical alzheimer; tau; novel tau ... See more keywords